ARTICLE | Clinical News

Eloctate RFVIIIFc regulatory update

October 20, 2014 7:00 AM UTC

Biogen Idec submitted an MAA to EMA for Elocta to treat hemophilia A. Swedish Orphan said the submission triggered its exclusive opt-in right to assume final development and commercialization of the product in Europe, Russia, the Middle East and Northern Africa (see BioCentury, Feb. 13, 2012). Swedish Orphan has 2 months to exercise the option. ...